These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 37717263)
1. Does the intensity of dissociation predict antidepressant effects 24 hours after infusion of racemic ketamine and esketamine in treatment-resistant depression? A secondary analysis from a randomized controlled trial. Echegaray MVF; Mello RP; Magnavita GM; Leal GC; Correia-Melo FS; Jesus-Nunes AP; Vieira F; Bandeira ID; Caliman-Fontes AT; Telles M; Guerreiro-Costa LNF; Marback RF; Souza-Marques B; Lins-Silva DH; Santos-Lima C; Cardoso TA; Kapczinski F; Lacerda ALT; Quarantini LC Trends Psychiatry Psychother; 2023 Sep; ():. PubMed ID: 37717263 [TBL] [Abstract][Full Text] [Related]
2. Reconsidering "dissociation" as a predictor of antidepressant efficacy for esketamine. Mathai DS; Nayak SM; Yaden DB; Garcia-Romeu A Psychopharmacology (Berl); 2023 Apr; 240(4):827-836. PubMed ID: 36729145 [TBL] [Abstract][Full Text] [Related]
3. Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial. Mello RP; Echegaray MVF; Jesus-Nunes AP; Leal GC; Magnavita GM; Vieira F; Caliman-Fontes AT; Telles M; Guerreiro-Costa LNF; Souza-Marques B; Bandeira ID; Santos-Lima C; Marback RF; Correia-Melo FS; Lacerda ALT; Quarantini LC J Psychiatr Res; 2021 Jun; 138():576-583. PubMed ID: 33991996 [TBL] [Abstract][Full Text] [Related]
4. Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression. Chen G; Chen L; Zhang Y; Li X; Lane R; Lim P; Daly EJ; Furey ML; Fedgchin M; Popova V; Singh JB; Drevets WC Int J Neuropsychopharmacol; 2022 Apr; 25(4):269-279. PubMed ID: 35022754 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Tolerability of Two Novel "Standard of Care" Treatments-Intranasal Esketamine Versus Intravenous Ketamine-for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study. Gutierrez G; Rosenblat J; Hawken E; Swainson J; Vazquez G JMIR Res Protoc; 2022 May; 11(5):e34711. PubMed ID: 35604752 [TBL] [Abstract][Full Text] [Related]
6. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression. Lineham A; Avila-Quintero VJ; Bloch MH; Dwyer J J Child Adolesc Psychopharmacol; 2023 Feb; 33(1):20-26. PubMed ID: 36799961 [No Abstract] [Full Text] [Related]
8. Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study. Singh JB; Fedgchin M; Daly E; Xi L; Melman C; De Bruecker G; Tadic A; Sienaert P; Wiegand F; Manji H; Drevets WC; Van Nueten L Biol Psychiatry; 2016 Sep; 80(6):424-431. PubMed ID: 26707087 [TBL] [Abstract][Full Text] [Related]
9. Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD. Williamson D; Turkoz I; Wajs E; Singh JB; Borentain S; Drevets WC Int J Neuropsychopharmacol; 2023 Mar; 26(3):198-206. PubMed ID: 36525338 [TBL] [Abstract][Full Text] [Related]
10. Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials. Saad Z; Hibar D; Fedgchin M; Popova V; Furey ML; Singh JB; Kolb H; Drevets WC; Chen G Int J Neuropsychopharmacol; 2020 Dec; 23(9):549-558. PubMed ID: 32367114 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH Focus (Am Psychiatr Publ); 2022 Apr; 20(2):241-251. PubMed ID: 37153136 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant. Floden L; Hudgens S; Jamieson C; Popova V; Drevets WC; Cooper K; Singh J CNS Drugs; 2022 Jun; 36(6):649-658. PubMed ID: 35441931 [TBL] [Abstract][Full Text] [Related]
18. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant. Hudgens S; Floden L; Blackowicz M; Jamieson C; Popova V; Fedgchin M; Drevets WC; Cooper K; Lane R; Singh J J Affect Disord; 2021 Feb; 281():767-775. PubMed ID: 33261932 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials. Jones RR; Freeman MP; Kornstein SG; Cooper K; Daly EJ; Canuso CM; Nicholson S Arch Womens Ment Health; 2022 Apr; 25(2):313-326. PubMed ID: 34973081 [TBL] [Abstract][Full Text] [Related]
20. Impact of Repeated Doses of Subcutaneous Esketamine on Acute Dissociative Symptoms in Treatment-Resistant Depression. Del Sant LC; Sarin LM; Lucchese AC; Magalhães EJM; Tuena MA; Nakahira C; Del Porto JA; De Lacerda ALT; Mari JJ Pharmaceuticals (Basel); 2022 Dec; 16(1):. PubMed ID: 36678528 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]